Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A spate of good news electrified investors in this cancer-focused medical device maker.

Why NovoCure Stock Skyrocketed 152% in 2019

Buy NovoCure: The First Mover In The New Modality In Cancer Treatment

NovoCure: I Still Like What I See

An analyst downgrade puts short-term pressure on the medical-device company's share price.

Here's Why Novocure Slipped Lower Today

NovoCure Making Remarkable Progress; Buy

This medical device maker's stock has gained an electrifying 166% in 2019.

Why NovoCure Stock Soared 29% in November

Cutera

Nevro

These companies have a lot to offer their patients and plenty of room to grow.

3 Medtech Companies to Watch

argenx

Galapagos

Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.

These 3 European Biotechs Can Help Recession-Proof Your Portfolio

NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript

NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know

Novocure stock has pulled back 20% since its all time highs in August 2019 (likely due to insider selling).

Buy The Fear In Novocure

This stock idea is totally out of range for TheMoneyMadam except for one metric and that is call option potential; that potential allows you to generate income on a non-dividend stock.

NovoCure: Call Option Potential

Shares of this oncology-focused medical device company continue their electrifying run.

Why NovoCure Stock Soared 32% in July

As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).

NovoCure Limited (NVCR) Shares March Higher, Can It Continue?

Shares jump after the company reports strong quarterly results and management shares some news about Medicare.

Why NovoCure Stock Is Surging Today

The innovative oncology company posted 41% revenue growth and achieved positive operating income for the first time in its history.

NovoCure Nears Profitability as Revenue Continues to Soar

Novocure's (NVCR) CEO Asaf Danziger on Q2 2019 Results - Earnings Call Transcript

NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.

Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?

Recently, NovoCure announced the CMC had granted coverage for Optune in use of patients with newly-diagnosed glioblastoma.

NovoCure Removes Overhang, Secures CMC Coverage For Newly-Diagnosed GBM

NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NovoCure (NVCR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Shares of this medical device company continue their electrifying 2019 run.

Why NovoCure Stock Jumped 19% in June

Amgen

Exelixis

These three businesses are a great way for investors to support the war on cancer.

3 Cancer-Treatment Stocks to Buy

NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

NovoCure (NVCR) Jumps: Stock Rises 7.1%

CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 190,338 shares of NVCR on 06/18/2019 at an average price of $59.37 a share.

News for Novocure Stock (NVCR)